Labiotech.eu

News and Trends 16 Dec 2022

Alchemab Therapeutics receives £1.7M grant to work on therapy for Huntington’s disease

Alchemab Therapeutics has been awarded a grant of £1.7 million ($2 million) from Innovate UK’s Biomedical Catalyst (BMC) 2022 funding competition to accelerate development of a first-in-class disease modifying therapy for Huntington’s disease. Working in collaboration with Medicines Discovery Catapult (MDC), Alchemab is carrying out preclinical studies to progress its panel of antibodies towards first […]

December 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Sosei Heptares and Lilly enter agreement on diabetes and metabolic diseases

Sosei Group Corporation has entered a drug discovery collaboration with Eli Lilly and Company to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with diabetes and metabolic diseases. The agreement will leverage Sosei Heptares’ StaR technology and structure-based drug design (SBDD) platform and Lilly’s drug development and commercialization […]

December 16, 2022 - 2 minutesmins - By Jim Cornall

In Depth 15 Dec 2022

To avoid stagnation, the EU must refine its ATMP regulation

Over the decades, the EU has spearheaded the adoption of advanced therapy medicinal products (ATMPs) such as cell and gene therapies. However, changes are needed to ATMP regulations to keep Europe competitive with the rest of the world. The EU has a rich resource base in terms of biotech innovation. Over the last decades, this […]

December 15, 2022 - 8 minutesmins - By Jonathan Smith

News and Trends 15 Dec 2022

MinervaX raises €72M to develop Group B Streptococcus vaccine

MinervaX ApS, a privately held Danish biotech company developing a novel vaccine against Group B Streptococcus (GBS), has completed a €72 million ($76.5 million) financing round. The equity financing of €22 million ($23.4 million) was co-led by new investors Trill Impact Ventures and Pureos Bioventures and includes existing investors REPAIR Impact Fund (Novo Holdings), Sunstone […]

December 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

European Commission approves Dupixent as first and only targeted prurigo nodularis medicine

The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials […]

December 15, 2022 - 5 minutesmins - By Jim Cornall

cardiology cardiovascular disease heart attack

News and Trends 15 Dec 2022

Cell reprogramming can reverse fibrosis after heart attack

Researchers in Japan may have found a way to repair cardiac damage in patients suffering from chronic heart attack and heart failure. In a study published in Circulation, researchers from the University of Tsukuba have revealed that changing heart cell programming by tweaking the expression of a few key genes can actually reverse the lasting […]

December 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

Charcot-Marie-Tooth study to get $250K grant

The Muscular Dystrophy Association (MDA) and Charcot-Marie-Tooth Research Foundation (CMTRF) have announced joint funding for a study by Alessandra Bolino at San Raffaele Hospital (Ospedale San Raffaele), Italy, on restoring membrane trafficking in Charcot-Marie-Tooth (CMT) neuropathies with aberrant myelin. This will be a three-year study, with the grant totaling $263,450. “We at the Muscular Dystrophy […]

December 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

EMA gives Myrtelle’s Canavan disease gene therapy candidate OD designation

Myrtelle Inc., a clinical stage gene therapy company, has announced that the European Medicines Agency (EMA) has granted orphan drug (OD) designation for rAAV-Olig001-ASPA, the company’s lead gene therapy product candidate for the treatment of Canavan disease (CD). EMA OD designation’s aim is to encourage the development of treatments for life-threatening rare conditions by providing […]

December 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

Solve Therapeutics launches to tackle cancer

Solve Therapeutics, Inc. (SolveTx), an oncology-focused biopharmaceutical company, has launched with the mission of developing novel antibody-based therapies targeting tumor-specific antigens. The company’s formation reunites the former VelosBio Inc. team. SolveTx is fully operational with more than 25 employees and is actively pursuing discovery and development efforts at its 10,000-square-foot laboratory in San Diego. Solve […]

December 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

Cyclica and SK Chemicals to co-develop novel therapeutics

Cyclica Inc. and SK Chemicals Co., Ltd. have announced an AI-driven drug discovery and development partnership to develop therapies across a range of disease areas. Under this collaboration, Cyclica will deploy its proprietary drug discovery platforms to identify novel drug candidates for challenging biological targets across therapeutic areas of mutual interest to both companies. SK […]

December 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

Replay targets genetic brain disorders with new gene therapy company, Kaleibe

Replay, a genome writing company, today announced the launch of Kaleibe, an HSV gene therapy company targeting genetic brain disorders. It is the third of Replay’s product companies to launch since the company’s formation in July and will leverage Replay’s high payload capacity herpes simplex virus (HSV) delivery vector, synHSV, to target genetic brain disorders. […]

December 14, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

STORM Therapeutics closes $30M Series B financing

STORM Therapeutics Ltd., which is working on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, has successfully completed a $30 million Series B financing round. The financing was co-led by existing investors M Ventures, Pfizer Ventures, Taiho Ventures LLC, Cambridge Innovation Capital (CIC) and new investors […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Alchemab Therapeutics receives £1.7M grant to work on therapy for Huntington’s disease

Sosei Heptares and Lilly enter agreement on diabetes and metabolic diseases

To avoid stagnation, the EU must refine its ATMP regulation

MinervaX raises €72M to develop Group B Streptococcus vaccine

European Commission approves Dupixent as first and only targeted prurigo nodularis medicine

Cell reprogramming can reverse fibrosis after heart attack

Charcot-Marie-Tooth study to get $250K grant

EMA gives Myrtelle’s Canavan disease gene therapy candidate OD designation

Solve Therapeutics launches to tackle cancer

Cyclica and SK Chemicals to co-develop novel therapeutics

Replay targets genetic brain disorders with new gene therapy company, Kaleibe

STORM Therapeutics closes $30M Series B financing

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!